Pharmacokinetic drug-drug interaction assessment between LCZ696, an angiotensin receptor neprilysin inhibitor, and hydrochlorothiazide, amlodipine, or carvedilol

Clinical Pharmacology in Drug Development

Volumn 4, Issue 6, 2015, Pages 407-417

  Hsiao, Hsiu ling ^a   Langenickel, Thomas Heiko ^b   Greeley, Michael ^b   Roberts, John ^b   Zhou, Wei ^a   Pal, Parasar ^c   Rebello, Sam ^a   Rajman, Iris ^b   Sunkara, Gangadhar ^a  

^a NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

^c NOVARTIS HEALTHCARE PVT LTD   (India)

Author keywords

Amlodipine; Carvedilol; Hydrochlorothiazide; LCZ696; Pharmacokinetic drug drug interaction

Indexed keywords

3 (1 BIPHENYL 4 YLMETHYL 3 CARBOXY 1 BUTYLCARBAMOYL)PROPIONIC ACID; AMLODIPINE; CARVEDILOL; HYDROCHLOROTHIAZIDE; SACUBITRIL; SACUBITRIL PLUS VALSARTAN; VALSARTAN; AMINOBUTYRIC ACID DERIVATIVE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CARBAZOLE DERIVATIVE; DIURETIC AGENT; MEMBRANE METALLOENDOPEPTIDASE; PROPANOLAMINE DERIVATIVE; PROTEINASE INHIBITOR; TETRAZOLE DERIVATIVE;

ADULT; ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG EFFECT; DRUG ISOLATION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; GASTROESOPHAGEAL REFLUX; GENERALIZED PRURITUS; HEADACHE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; LIMB PAIN; MALE; MASS SPECTROMETRY; NORMAL HUMAN; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; PRURITUS; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT DURATION; UPPER ABDOMINAL PAIN; URINARY TRACT INFECTION; ANTAGONISTS AND INHIBITORS; AREA UNDER THE CURVE; ARIZONA; BIOLOGICAL MODEL; BLOOD; CLINICAL TRIAL; COMBINATION DRUG THERAPY; DRUG ADMINISTRATION; DRUG INTERACTION; METABOLIC CLEARANCE RATE; METABOLISM; MIDDLE AGED; ORAL DRUG ADMINISTRATION;

ADMINISTRATION, ORAL; ADRENERGIC BETA-ANTAGONISTS; ADULT; AMINOBUTYRATES; AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONISTS; ANTIHYPERTENSIVE AGENTS; AREA UNDER CURVE; ARIZONA; CALCIUM CHANNEL BLOCKERS; CARBAZOLES; CROSS-OVER STUDIES; DIURETICS; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; FEMALE; HEALTHY VOLUNTEERS; HUMANS; HYDROCHLOROTHIAZIDE; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; MODELS, BIOLOGICAL; NEPRILYSIN; PROPANOLAMINES; PROTEASE INHIBITORS; TETRAZOLES;

EID: 84954380863     PISSN: 2160763X     EISSN: 21607648     Source Type: Journal    
DOI: 10.1002/cpdd.183     Document Type: Article

References (33)

1. Gu J, Noe A, Chandra P, et al. Pharmacokinetics and pharmacodynamics of LCZ696, a novel dual-acting angiotensin receptor-neprilysin inhibitor (ARNi). J Clin Pharmacol. 2010; 50:401-414.
2. Kishimoto I, Tokudome T, Nakao K, Kangawa K. Natriuretic peptide system: an overview of studies using genetically engineered animal models. FEBS J. 2011; 278:1830-1841.
3. de Bold AJ. Thirty years of research on atrial natriuretic factor: historical background and emerging concepts. Can J Physiol Pharmacol. 2011; 89:527-531.
4. Potter L, Yoder A, Flora D, Antos K, Dickey M. Natriuretic peptides: their structures, receptors, physiologic functions and therapeutic applications. Handb Exp Pharmacol. 2009; 191:341-358.
5. Kuhn M. Function and dysfunction of mammalian membrane guanylyl cyclase receptors: lessons from genetic mouse models and implications for human diseases. Handb Exp Pharmacol. 2009; 191:47-69.
6. Porzionato A, Macchi V, Rucinski M, et al. Natriuretic peptides in the regulation of the hypothalamic-pituitary-adrenal axis. Int Rev Cell Mol Biol. 2010; 280:1-39.
7. Moro C, Lafontan M. Natriuretic peptides and cGMP signaling control of energy homeostasis. Am J Physiol Heart Circ Physiol. 2013; 304:H358-H368.
8. Mehta P, Griendling KK. Angiotensin II cell signaling: physiological and pathological effects in the cardiovascular system. Am J Physiol Cell Physiol. 2007; 292:C82-C97.
9. Weir MR, Dzau VJ. The renin-angiotensin-aldosterone system: a specific target for hypertension management. Am J Hypertens. 1999; 12:205S-213S.
10. Langenickel TH, Dole WP. Angiotensin receptor-neprilysin inhibition with LCZ696: a novel approach for the treatment of heart failure. Drug Discov Today. 2012; 9(4):e131-e139.
11. ESH/ESC Guidelines for the management of arterial hypertension. J Hypertens. 2013; 31:1281-1357.
12. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012. Eur Heart J. 2012; 33:1787-847.
13. Packer M, Fowler MB, Roecker EB, et al. Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study. Circulation. 2002; 106(17):2194-2199.
14. Dargie HJ. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet. 2001; 357(9266):1385-1390.
15. Waldmeier F, Flesch G, Mueller P, et al. Pharmacokinetics, disposition and biotransformation of [14C]-radiolabelled valsartan in healthy male volunteers after a single oral dose. Xenobiotica. 1997; 27:59-71.
16. Nakashima A, Kawashita H, Masuda N, et al. Identification of cytochrome P450 forms involved in the 4-hydroxylation of valsartan, a potent and specific angiotensin II receptor antagonist, in human liver microsomes. Xenobiotica. 2005; 35(6):589-602.
17. Taavitsainen P, Kiukaanniemi K, Pelkonen O. In vitro inhibition screening of human hepatic P450 enzymes by five angiotensin II receptor antagonists. Eur J Clin Pharmacol. 2000; 56:135-140.
18. Du Y, Chandra P, Alshare Q, et al. An open-label, single dose study to investigate the absorption, distribution, metabolism, and elimination of [14C]-LCZ696 and its metabolites in healthy male subjects. Poster session presented at: 2013 AAPS Annual Meeting and Exposition; November 10-14, 2013; San Antonio, TX.
19. Beermann B, Groschinsky-Grind M. Pharmacokinetics of hydrochlorothiazide in man. Eur J Clin Pharmacol. 1977; 12:297-303.
20. Zhu Y, Wang F, Li Q, et al. Metabolism of amlodipine in human liver microsomes and roles of CYP3A in amlodipine dehydrogenation. Drug Metab Dispos. 2014; 42:245-249.
21. Tenero D, Boike S, Boyle D, et al. Steady-state pharmacokinetics of carvedilol and its enantiomers in patients with congestive heart failure. J Clin Pharmacol. 2000; 40:844.
22. Oldham HG, Clarke SE. In vitro identification of the human cytochrome P450 enzymes involved in the metabolism of R(+)- and S(-)-carvedilol. Drug Metab Dispos. 2014; 42:245-249.
23. Yamashiro W, Maeda K, Hirouchi M, et al. Involvement of transporters in the hepatic uptake and biliary excretion of valsartan, a selective antagonist of the angiotensin ii at1-receptor, in humans. Drug Metabol Dispos. 2006; 34:1247-1254.
24. Huo X, Liu Q, Qang C, et al. Inhibitory effect of valsartan on the intestinal absorption and renal excretion of bestatin in rats. J Pharm Sci. 2014; 103:719-729.
25. Bachmakov I, Werner U, Endress B, Auge D, Fromm MF. Characterization of beta-adrenoceptor antagonists as substrates and inhibitors of the drug transporter P-glycoprotein. Fundam Clin Pharmacol. 2006; 20(3):273-282.
26. Wermeling DP, Field CJ, Smith DA, Chandler MH, Clifton GD, Boyle DA. Effects of long-term oral carvedilol on the steady-state pharmacokinetics of oral digoxin in patients with mild to moderate hypertension. Pharmacotherapy. 1994; 14(5):600-606.
27. Sunkara G, Reynolds CV, Pommier F, et al. Evaluation of a pharmacokinetic interaction between valsartan and simvastatin in healthy subjects. Curr Med Res Opin. 2007; 23:631-640.
28. Sunkara G, Yeh C, Ligueros-Saylan M, Kawashita H, Koseki N, Fukui Y. Assessment of ethnic differences in the pharmacokinetics and pharmacodynamics of valsartan. J Bioequiv Availab. 2010; 2(6):120-124.
29. Tenero D, Boyle D, Cyronak M, et al. Intersubject and intrasubject variability in the pharmacokinetics of carvedilol. Pharmacotherapy. 1990; 10:245.
30. Solomon SD, Zile M, Pieske B, et al. The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial. Lancet. 2012; 380:1387-1395.
31. Segura J, Salazar J, Ruilope LM. Dual neurohormonal intervention in CV disease: angiotensin receptor and Neprilysin inhibition. Expert Opin Investig Drugs. 2013; 22:915-925.
32. Chobanian AV, Bakris GL, Black HR, et al. The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure. JAMA. 2003; 289:2560-2572.
33. Plosker GL, Robinson DM. Amlodipine/valsartan fixed-dose combination in hypertension. Drugs. 2008; 68(3):373-381.